Gervois N - Search Results

1

Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients.

Labarrière N, Pandolfino MC, Gervois N, Khammari A, Tessier MH, Dréno B, Jotereau F. Labarrière N, et al. Among authors: gervois n. Cancer Immunol Immunother. 2002 Nov;51(10):532-8. doi: 10.1007/s00262-002-0313-3. Epub 2002 Sep 18. Cancer Immunol Immunother. 2002. PMID: 12384804 Free PMC article. Clinical Trial.

2

Specificity, T cell receptor diversity and activation requirements of CD4+ and CD8+ clones derived from human melanoma-infiltrating lymphocytes.

Pandolfino MC, Viret C, Gervois N, Guilloux Y, Davodeau F, Diez E, Jotereau F. Pandolfino MC, et al. Among authors: gervois n. Eur J Immunol. 1992 Jul;22(7):1795-802. doi: 10.1002/eji.1830220719. Eur J Immunol. 1992. PMID: 1623924

3

Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements.

Gervois N, Heuze F, Diez E, Jotereau F. Gervois N, et al. Eur J Immunol. 1990 Apr;20(4):825-31. doi: 10.1002/eji.1830200417. Eur J Immunol. 1990. PMID: 1971794

4

High proliferative capacity and specific antiautologous melanoma cytotoxicity of a human T-lymphocyte clone derived from tumor-infiltrating lymphocytes.

Gervois N, Heuze F, Diez E, Jotereau F. Gervois N, et al. Hum Immunol. 1990 Jun;28(2):112-8. doi: 10.1016/0198-8859(90)90006-b. Hum Immunol. 1990. PMID: 2141008

5

Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro.

Guilloux Y, Viret C, Gervois N, Le Dréan E, Pandolfino MC, Diez E, Jotereau F. Guilloux Y, et al. Among authors: gervois n. Eur J Immunol. 1994 Sep;24(9):1966-73. doi: 10.1002/eji.1830240905. Eur J Immunol. 1994. PMID: 7522155

6

HLA class II-restricted recognition of common tumor epitopes on human melanoma cells by CD4+ melanoma-infiltrating lymphocytes.

Le Dréan E, Gervois N, Diez E, Semana G, Dreno B, Jotereau F. Le Dréan E, et al. Among authors: gervois n. Eur J Immunol. 1995 Oct;25(10):2732-6. doi: 10.1002/eji.1830251003. Eur J Immunol. 1995. PMID: 7589064

7

T cell activation by antigens on human melanoma cells--co-stimulation by B7-1 is neither sufficient nor necessary to stimulate IL-2 secretion by melanoma-specific T cell clones in vitro.

Viret C, Gervois N, Guilloux Y, Le Dréan E, Diez E, Jotereau F. Viret C, et al. Among authors: gervois n. Int Immunol. 1995 Oct;7(10):1535-43. doi: 10.1093/intimm/7.10.1535. Int Immunol. 1995. PMID: 8562498

8

Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions.

Gervois N, Guilloux Y, Diez E, Jotereau F. Gervois N, et al. J Exp Med. 1996 May 1;183(5):2403-7. doi: 10.1084/jem.183.5.2403. J Exp Med. 1996. PMID: 8642353 Free PMC article.

9

Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma.

Romero P, Gervois N, Schneider J, Escobar P, Valmori D, Pannetier C, Steinle A, Wolfel T, Lienard D, Brichard V, van Pel A, Jotereau F, Cerottini JC. Romero P, et al. Among authors: gervois n. J Immunol. 1997 Sep 1;159(5):2366-74. J Immunol. 1997. PMID: 9278327

10

Heterogeneity of biologic responses of melanoma-specific CTL.

Fonteneau JF, Le Dréan E, Le Guiner S, Gervois N, Diez E, Jotereau F. Fonteneau JF, et al. Among authors: gervois n. J Immunol. 1997 Sep 15;159(6):2831-9. J Immunol. 1997. PMID: 9300706

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Search Page

Filters